BFS
ZBIO

Bare Financial Services’s Zenas BioPharma ZBIO Stock Holding History

Bare Financial Services’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41K Buy
95
+81
+579% +$1.61K ﹤0.01% 1090
2026
Q1 		$274 Buy
+14
New +$314 ﹤0.01% 1713

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Bare Financial Services's ZBIO Position: Q2 2026 in Review

Bare Financial Services increased its Zenas BioPharma (ZBIO) stake by 579% in Q2 2026, buying an estimated $1.61K and bringing the position to 95 shares worth $2.41K. The position accounts for ﹤0.01% of the portfolio, ranked #1090.

Bare Financial Services first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Bare Financial Services held 95 shares of Zenas BioPharma worth $2.41K as of Q2 2026.
  • Bare Financial Services bought 81 Zenas BioPharma shares in Q2 2026, an estimated $1.61K.
  • Zenas BioPharma made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1090 holding.
  • Bare Financial Services first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.